Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
Best Momentum Stock to Buy for August 8th
11:25am, Tuesday, 08'th Aug 2023
ACLS, BHC and JHX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2023.
Best Value Stocks to Buy for August 8th
09:56am, Tuesday, 08'th Aug 2023
BHC, GPI and UPBD made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 8, 2023.
New Strong Buy Stocks for August 8th
09:10am, Tuesday, 08'th Aug 2023
ISNPY, SWDBY, MKL, GPI and BHC have been added to the Zacks Rank #1 (Strong Buy) List on August 8, 2023.
Bausch Health's (BHC) Q2 Earnings & Sales Beat, '23 View Raised
02:17pm, Friday, 04'th Aug 2023
Bausch's (BHC) second-quarter earnings and sales surpass estimates. The company increases its revenue guidance for 2023.
Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say
12:00pm, Thursday, 03'rd Aug 2023
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street est
Bausch Health Companies Inc. (BHC) Q2 2023 Earnings Call Transcript
11:50am, Thursday, 03'rd Aug 2023
Bausch Health Companies Inc. (NYSE:BHC ) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Thomas Appio - CEO Tom Vadaketh - CFO John O'Connor - SVP, IR Conference Call P
Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3
08:00am, Thursday, 13'th Jul 2023
LAVAL, QC / ACCESSWIRE / July 13, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release its second-quarter financial results on Thursday, Aug. 3, 2023. Bausch Health will host a conference c
Bausch Health (BHC) Secures $600M Financing Facility, Stock Up
01:15pm, Monday, 10'th Jul 2023
Bausch (BHC) enters into a $600 million non-recourse financing facility with KKR to boost liquidity.
Why Shares of Bausch Health Jumped on Friday
03:16pm, Friday, 07'th Jul 2023
The pharmaceutical company has entered into a $600 million financing facility with investment management giant KKR. Bausch said it plans to use the extra funds for general corporate purposes.
Bausch Health's stock rallies after $600 million financing agreement with KKR
08:24am, Friday, 07'th Jul 2023
Shares of Bausch Health Companies Inc. BHC, -1.03% rallied 2.1% in premarket trading Friday, after the pharmaceutical company announced a $600 million financing facility with KKR & Co. Inc. KKR, -2.46
Bausch + Lomb Buys Blink Brands to Expand Eye Drop Portfolio
04:55pm, Thursday, 06'th Jul 2023
Bausch + Lomb purchased Blink brands from a J&J subsidiary for $106.5 million to expand its over-the-counter offerings.
Bausch + Lomb buys J&J's dry eye relief drops for $107 mln
07:24am, Thursday, 06'th Jul 2023
Bausch + Lomb said on Thursday it has acquired Johnson & Johnson's eye and contact lens drops for $106.5 million in an all-cash deal to expand its portfolio of over-the-counter eye care products.
Bausch + Lomb Buys Novartis Drugs for $1.75 Billion Expanding Eye Care Portfolio
03:45pm, Friday, 30'th Jun 2023
Eye care company Bausch + Lomb said it would pay $1.75 billion to acquire a portfolio of eye care products from Swiss healthcare giant Novartis.
Bausch + Lomb to acquire dry eye treatment from Novartis in potential $2.5B deal
10:13am, Friday, 30'th Jun 2023
Bausch + Lomb Corp has announced plans to buy dry eye disease treatment Xiidra from Swiss pharma giant Novartis AG (ADR) (NYSE:NVS) in a deal that could be valued as high as $2.5 billion. The two comp
Bausch + Lomb to buy ‘dry eye' treatment from Novartis in a $2.5 billion deal
09:33am, Friday, 30'th Jun 2023
Bausch + Lomb Corp. BLCO, +7.98% confirmed that it was buying the “dry eye” treatment Xiidra from Novartis AG NVS, +0.90% NOVN, +0.72% in a deal valued at $2.5 billion. Under terms of the deal, Ba
